Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Undertreatment of Newly-Diagnosed MM Evaluated

Clin Lymphoma Myeloma Leuk; ePub 2018 Feb 3; Fakhri, et al

Certain age, health status, race, and socioeconomic factors appear to be linked with receiving no treatment for multiple myeloma (MM), according to a study involving nearly 4,200 individuals. Participants were from the 2007-2011 SEER-Medicare database and had plasma cell myeloma. Investigators looked at factors linked with receiving no treatment for MM. Among the results:

  • 373 had no claims showing MM treatment nor ICD-9 codes for MM-defining clinical features.
  • Of ~3,800 patients with active MM, 4 in every 10 had no claims for systemic treatment.
  • Patients who were older, had poor performance indicators, and had comorbidities were more likely to receive no systemic treatment.
  • The same was true for blacks, those with lower socioeconomic status, and patients receiving Medicaid.

Citation:

Fakhri B, Fiala M, Tuchman S, Wildes T. Undertreatment of older patients with newly diagnosed multiple myeloma in the era of novel therapies. [Published online ahead of print February 3, 2018]. Clin Lymphoma Myeloma Leuk. doi: 10.1016/j.clml.2018.01.005.

This Week's Must Reads

Widespread Zika screens not cost effective, Saá P et al. New Engl J Med. 2018;378:1778-88. doi: 10.1056/NEJMoa1714977

New cancer drugs linked to fewer arrhythmias, Nickel A et al. annual meeting of the American College of Cardiology ACC 18, Abstract #900-06.

Good ALL outcomes in Down syndrome children, Maloney K et al. ASPHO 2018, annual meeting of the American Society of Pediatric Hematology/Oncology Abstract PP 2001

Reducing morbidity in postpartum hemorrhage, Smith R et al. Annual clinical and scientific meeting of the American Society of Obstetricians and Gynecologists 2018, Abstract 26R.

In sickle cell, start hydroxyurea in infancy, Schuchard S et al. ASPHO 2018, poster # 342 Schuchard S et al. ASPHO 2018, poster # 342. https://onlinelibrary.wiley.com/doi/10.1002/pbc.27057

Must Reads in Myelodysplastic Syndrome

Romiplostim safety confirmed in thrombocytopenic patients with low-risk myelodysplastic syndromes, Kantarjian H et al. The Lancet Haematology March 2018, Pages e117-e126 https://doi.org/10.1016/S2352-3026(18)30016-4

Simplifying the URD Selection Process for HCT, Biol Blood Marrow Transplant.; ePub 2018 Feb 14; Shaw, Logan, et al

Genetic Risk Model for MDS Shown to Be Feasible, Am J Hematol; ePub 2018 Feb 24; Gangat, et al

This Predicts Risk of Early Relapse, Death in MM , Biol Blood Marrow Transplant; ePub 2018 Feb 23; Cowan, et al

Undertreatment of Newly-Diagnosed MM Evaluated, Clin Lymphoma Myeloma Leuk; ePub 2018 Feb 3; Fakhri, et al